Skip to content Skip to sidebar Skip to footer

From “Soft Landing” to “Soft Thud”: What February Jobs Say Before the Fed Meets -( $DIA $QQQ $SPY $VIX )

The latest jobs report delivered a jolt to Wall Street’s morning coffee, but not quite the recession-grade earthquake some feared.

Jobs Growth Slams Into Reverse

The US economy unexpectedly shed 92,000 jobs in February, abruptly ending the early‑year hiring momentum. Economists had penciled in a gain of about 55,000 to 60,000 payrolls, making the actual print a sizable miss and a clear downside surprise. The unemployment rate ticked up to 4.4%, marking a visible loosening in what had long been described as a relentlessly tight labor market.

Revisions added a further pinch of humility to forecasters’ pride: January’s 130,000-job gain was nudged down by 4,000, while December’s reported increase of 48,000 was reclassified as a 17,000-job loss. Taken together, those changes sliced a net 69,000 jobs from the prior two reports, underscoring that the cooling trend is not just a one‑off.

Under The Hood: A Labor Market Losing Its Glow

Beneath the headline, the softening story becomes harder to ignore. The share of workers unemployed for 27 weeks or more climbed to 25.3% of all jobless individuals, a shift that speaks less of frictional job changes and more of persistent scarring. Commentators who had warned that momentum was fading took something of a victory lap, dubbing the report “ugly” and casting it as a win for the pessimistic “Team Doomer” over the more exuberant “Team Reacceleration.”

Sector performance added nuance rather than outright despair. Healthcare, which had been one of the most reliable engines of hiring, lost about 28,000 jobs in February, a decline driven largely by strike activity rather than broad‑based industry collapse. Social assistance roles, including home and personal care aides, offered one of the few bright spots, posting a gain of roughly 9,000 positions and highlighting how much the expansion has come to depend on services tied to care and support.

Strikes, Signals, And The “Is This It?” Question

The healthcare losses offer a reminder that not every negative jobs print signals a macro cliff. A major strike involving roughly 31,000 workers in California weighed heavily on the February figures, demonstrating that labor disputes can turn a fundamentally mediocre report into a statistically alarming one. For investors, the task now is to separate cyclical weakness from one‑off distortions without resorting to either complacency or melodrama.

Still, after months of resilience, a cleanly negative payrolls number carries psychological weight on Wall Street screens. An unemployment rate at 4.4% is not historically high, but the direction matters more than the level when markets are trying to map out the next move in policy and profits. Put differently: the US labor market may not be rolling over, but it has definitely stopped flexing in the mirror.

What It Means For The Fed’s March Playbook

For the Federal Reserve, this report arrives like an unexpected memo from reality taped to the door of a long inflation‑centric discussion. Softer payrolls and a higher jobless rate tilt the balance of risks toward growth rather than just prices, giving policymakers a fresh reason to at least talk about future easing, even if they are not yet ready to pull the trigger. Markets that once fretted over “higher for longer” now have license to entertain “gentler, maybe sooner,” though one month’s data rarely rewrites an entire policy script.insight.

The timing matters. The next Federal Open Market Committee meeting is scheduled for March 17–18, 2026, a gathering that instantly becomes more consequential in light of the February payrolls stumble. Chair Jerome Powell and his colleagues will walk into that two‑day session with a labor market that looks less overheated and a public increasingly attentive to job security as much as price stability.

Markets, Mood, And The Art Of Not Overreacting

For equity investors, the February jobs report is likely to revive a familiar, if slightly exhausted, balancing act. On one hand, weaker employment data can pressure corporate earnings, particularly in cyclical sectors that rely on robust hiring and consumer confidence. On the other, a cooler labor market eases wage pressures and may soften the Fed’s stance over time, an environment in which long‑duration assets and rate‑sensitive names often find new admirers.

In fixed income, the narrative may tilt toward lower yields as traders price in a greater chance that the Fed will eventually pivot from vigilance to accommodation. Volatility around the March meeting is almost assured, but panic is not pre‑ordained; a single weak month, even with sobering revisions, does not erase years of job gains or the economy’s still‑solid baseline. For now, the February report reads less like the final chapter of an expansion and more like a pointed editorial note in the margin: slow down, pay attention, and stop assuming every plot twist ends the story.

The Sources


Yahoo Finance – “Jobs report shocks with unexpected loss of 92,000 jobs in February as unemployment rate rises”
https://finance.yahoo.com/news/jobs-report-shocks-with-unexpected-loss-of-92000-jobs-in-february-as-unemployment-rate-rises-200907904.html[finance.yahoo]​
Yahoo Finance – “U.S. loses 92,000 jobs in February as unemployment rises”
https://finance.yahoo.com/news/u-loses-92-000-jobs-150027874.html[finance.yahoo]​
Yahoo Finance – “US economy unexpectedly sheds 92,000 jobs in February”
https://finance.yahoo.com/news/us-economy-unexpectedly-sheds-92-135333086.html[finance.yahoo]​
FactSet – “Total Nonfarm Payrolls For February 2026 Are Projected To Rise By 60,000”
https://insight.factset.com/total-nonfarm-payrolls-for-february-2026-are-projected-to-rise-by-60000[insight.factset]​
Trading Economics – “United States Non Farm Payrolls”
https://tradingeconomics.com/united-states/non-farm-payrolls[tradingeconomics]​
First Trust – “Nonfarm Payrolls Increased 130,000 in January”
https://www.ftportfolios.com/blogs/EconBlog/2026/2/11/nonfarm-payrolls-increased-130,000-in-january[ftportfolios]​
Federal Reserve Board – “Calendar: March 2026” (FOMC schedule)
https://www.federalreserve.gov/newsevents/2026-march.htm[federalreserve]​
zForex – “2026 FOMC Meeting Schedule”
https://zforex.com/blog/general-trading/what-is-the-fomc-meeting-schedule/[zforex]​
Do you want a second list formatted specifically in HTML or Markdown for direct pasting into your site or newsletter?

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the California‑based biotech at approximately $2.5 billion. The deal, expected to close in the second quarter of 2026, is not just another check‑the‑box acquisition; it’s a calibrated wager on rare and pediatric cancers, where innovation still outpaces competition.


Why $2.5 Billion Makes Sense

Servier’s $2.5 billion price tag on Day One reflects far more than the sum of its pipeline slides. Day One brings a targeted oncology franchise anchored in pediatric low‑grade glioma (pLGG) and a broader portfolio of early‑ to late‑stage assets, all tailored to “high unmet medical needs.” Markets noticed: DAWN shares ramped on the news, a nod to the premium baked into the offer and the perceived scarcity of pure‑play pediatric‑weighted oncology assets on the public market.

From a corporate‑strategy lens, the price is less about multiples and more about optionality: Day One’s Phase 3 FIREFLY‑2 program in front‑line pLGG, combined with earlier‑stage solid‑tumor candidates, gives Servier a rare one‑two punch in a niche where clinical and pricing dynamics are more forgiving than in crowded adult‑drug markets.


Pediatric Low‑Grade Glioma: The Crown Jewel

At the heart of the deal sits tovorafenib (DAY101), Day One’s lead Type II RAF inhibitor for pediatric low‑grade glioma. FIREFLY‑1, the pivotal Phase 2 trial, showed meaningful responses in relapsed or progressive pLGG—a population that has long cycled through surgery, radiation, and chemotherapy while waiting for something better. The company is now running FIREFLY‑2, a Phase 3 front‑line study comparing tovorafenib against chemotherapy, with primary endpoints anchored on overall response rate and progression‑free survival, using Neuro‑Oncology‑aligned criteria.

For Servier, that’s a strategic trifecta: a pediatric franchise with a clear path to regulatory nods, a biomarker‑driven label story, and a relatively modest competitive landscape. In a world where many oncology acquisitions devolve into “me‑too” scrambles, Servier is positioning itself as the default acquirer for precision oncology aimed at children, not just adults.


A Pipeline, Not Just a Flagship

While pLGG is the headliner, Servier isn’t buying a single‑asset story. Day One’s portfolio includes Emi‑Le (emiltatug ledadotin), a Phase 1 agent targeting recurrent or advanced solid tumors, including adenoid cystic carcinoma and select breast, endometrial, and ovarian cancers. Separately, Day One’s DAY301 antibody‑drug conjugate program, directed against PTK‑7, is enrolling patients with locally advanced or metastatic solid tumors.

For Servier, those programs are less about near‑term revenue and more about option‑value signaling: they telegraph that the combined organization will be a destination for both pediatric and adult oncology innovators who want globally‑scaled development and commercial infrastructure. That’s a subtle but important message to venture‑backed biotechs eyeing their next strategic partner.


Servier’s Oncology Chessboard

Servier has long positioned itself as a “foundation‑owned” counterpoint to the hyperspeed deal‑making of Big Pharma. The Day One acquisition is a textbook example: rather than overpaying for a late‑stage blockbuster, Servier is thickening its rare oncology tile on the global board, layering on a pediatric‑heavy, targeted‑therapy axis that complements its existing portfolio.

Olivier Laureau, Servier’s president, framed the deal as a natural extension of the company’s 2030 ambition to prioritize “innovative treatments for patients with high unmet medical needs.” For Day One’s CEO, Jeremy Bender, the appeal is equally clear: Servier’s track record in rare cancers and its global infrastructure make it a better home for a pediatric‑focused franchise than going it alone through commercialization.


Investor and Market Implications

For investors, the transaction is a high‑conviction statement on the value of niche oncology assets that can be protected by both clinical need and regulatory tailwinds. Day One’s $2.5 billion equity price masks the real story: the premium is less about peak sales in a crowded indication and more about the optionality of a pediatric‑weighted pipeline in an era of targeted therapies.

From an M&A‑cycle perspective, the deal also hints at a broader trend: larger, well‑capitalized firms increasingly see pediatric and rare oncology as defensible, high‑value niches rather than afterthoughts. Servier’s foundation‑governed structure may even help it sidestep some of the short‑term earnings pressure that can make other buyers skittish around long‑cycle, high‑risk oncology programs.


A Touch of Sophisticated Humor: Big Pharma, Little Patients

If the biotech world is a board game, Servier’s acquisition of Day One looks less like a “hostile takeover” and more like a children’s chess club finally attracting a serious grandmaster. Pediatric oncology has long been the discipline that prides itself on punching above its weight: fewer patients, fewer dollars, but outsized scientific prestige. Servier is effectively betting that the “smaller” market is actually the more strategic one—where innovation can be both clinically meaningful and commercially rewarding without the usual gladiator‑style price pressure.

In that light, the deal is also a quiet rebuke to the industry’s obsession with “blockbuster” oncology labels. Instead of chasing the next 10‑figure lung‑cancer drug, Servier is doubling down on a pediatric‑centric, biomarker‑driven playbook—a move that could look more like foresight than niche‑play in hindsight.


The Sources

  1. Servier and Day One Biopharmaceuticals announce acquisition – Servier
    https://servier.com/en/newsroom/acquisition-day-one-biopharmaceuticals-rare-oncology/[servier]​
  2. Servier and Day One Biopharmaceuticals announce acquisition – GlobeNewswire
    https://www.globenewswire.com/news-release/2026/03/06/3251033/0/en/Servier-and-Day-One-Biopharmaceuticals-announce-acquisition-to-expand-Servier-s-rare-oncology-portfolio.html[globenewswire]​
  3. Day One Biopharmaceuticals acquired by Servier for $2.5B – StockTitan
    https://www.stocktitan.net/news/DAWN/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-r6fs0iuc7x22.html[stocktitan]​
  4. Servier to buy Day One Biopharmaceuticals for $2.5 billion – Reuters (via TradingView link)
    https://www.tradingview.com/news/reuters.com,2026:newsml_TUA7L63T6:0-servier-and-day-one-biopharmaceuticals-announce-acquisition/tradingview+1
  5. Day One Biopharma to be acquired by Servier for $2.5B – Seeking Alpha
    https://seekingalpha.com/news/4561872-day-one-biopharma-acquired-by-servier[seekingalpha]​
  6. Day One Biopharmaceuticals skyrockets on Servier’s $2.5 billion deal – Investor’s Business Daily
    https://www.investors.com/news/technology/day-one-biopharmaceuticals-seriver-acquisition/[investors]​
  7. Servier to Acquire Day One Biopharmaceuticals in Merger – TipRanks
    https://www.tipranks.com/news/company-announcements/servier-to-acquire-day-one-biopharmaceuticals-in-merger[tipranks]​
  8. Servier and Day One Biopharmaceuticals announce acquisition – Yahoo Finance
    https://finance.yahoo.com/news/servier-day-one-biopharmaceuticals-announce-133000565.html[finance.yahoo]​
  9. Servier to buy Day One for $2.5 Billion, Expanding Oncology Portfolio – Wall Street Journal
    https://www.wsj.com/business/deals/servier-to-buy-day-one-for-2-5-billion-expanding-oncology-portfolio-ba873b03[wsj]​
  10. Servier rounds out rare cancer offerings with $2.5B Day One buy – Fierce Pharma
    https://www.fiercepharma.com/pharma/servier-adopt-sibling-voranigo-25b-purchase-day-one-and-its-childhood-brain-tumor-med[fiercepharma]​
  11. Servier to buy Day One (NASDAQ: DAWN) in $2.5B cash deal – StockTitan SEC filing summary
    https://www.stocktitan.net/sec-filings/DAWN/8-k-day-one-biopharmaceuticals-inc-reports-material-event-d0be116199cd.html[stocktitan]​
  12. Fenwick Represents Day One Biopharmaceuticals in $2.5B Acquisition by Servier – Fenwick
    https://www.fenwick.com/insights/experience/fenwick-represents-day-one-biopharmaceuticals-in-2-5b-acquisition-by-servier[fenwick]​
  13. Servier to Buy Day One for $2.5 Billion to Expand in Cancer – Bloomberg Law
    https://news.bloomberglaw.com/mergers-and-acquisitions/servier-to-buy-day-one-for-2-5-billion-to-expand-in-oncology[news.bloomberglaw]​
  14. Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B – STAT News
    https://www.statnews.com/2026/03/06/servier-dayone-pediatric-cancer/[statnews]​

Formula 1 Hits Top Gear: How This Racing Empire Is Quietly Lapping Wall Street -( $AAPL $AMZN $CMCSA $FWONA $FWONK $LMOF.F $NFLX )

Formula 1 is roaring into the new season like a blue-chip stock breaking out of a long consolidation: higher revenues, richer media deals, and a global fan base that seems in no mood to lift its foot off the throttle.


F1 Becomes a Cash-Flow MachineLiberty Media’s Formula 1 franchise has quietly evolved from a niche motorsport into a full‑fledged global media property, and the numbers now read like an earnings beat rather than a race result. Revenue climbed to about $3.9 billion in 2025, up roughly 14% year over year, while operating profit jumped close to 28%, underscoring improving operating leverage as more fans pack grandstands and tune in worldwide.Teams are sharing in the upside, with payouts around $1.4 billion reflecting both robust profitability and the series’ increasingly franchise‑like economics. For investors tracking Liberty’s FWONK shares, analysts now see the sport as a high‑growth media asset, not just a cyclical live‑events play, with projected earnings per share growth north of 20% in both 2026 and 2027.


Streaming Wars on the Pit WallIf the old F1 business model was built on trackside hospitality and linear TV, the new playbook reads like a tech‑media merger deck. The current U.S. broadcast deal, reportedly at about $90 million annually, is set to be renegotiated as F1 targets something closer to $150 million a year, with streamers like Apple (AAPL), Netflix (NFLX), Amazon (AMZN), and legacy giants such as Comcast (CMCSA) all circling the rights package.This bidding scrum matters because media rights are now the sport’s pole‑position revenue driver, fueling that near‑double‑digit revenue growth and those rare‑air EPS projections. For F1, the strategy is elegantly simple: keep the product thrilling on Sunday, then sell it multiple times over via global broadcast, streaming, sponsorship, and spin‑off opportunities throughout the week.


Fans Turn Grand Prix Weekends Into Global FestivalsThe modern Grand Prix looks less like a race and more like a multi‑day live‑entertainment franchise with gasoline in the background. Attendance surged to roughly 675 million across events, up about 4%, while live viewership jumped 21%, signaling that F1 is capturing both “butts in seats” and “eyes on screens” at the same time.Promoters are leaning in, investing in upgraded circuits, revamped pit complexes, and off‑track entertainment to justify premium pricing and long‑term race contracts. From record crowds at circuits like Silverstone to destination events in Las Vegas and beyond, each race is becoming a high‑yield weekend that blends tourism, hospitality, and brand activations into a single, scalable playbook.


Drivers as Billion‑Dollar Brand AmbassadorsOn track, F1’s cast of characters doubles as a global marketing department. Top drivers such as Lewis Hamilton, Max Verstappen, and Lando Norris now sit among the highest earners in motorsport, thanks to multi‑year contracts layered with performance incentives, endorsements, and personal sponsorships.As the sport’s commercial footprint widens, driver valuations are rising alongside media rights, creating a virtuous cycle where star power attracts sponsors, sponsors grow the pie, and the pie finances more competitive racing. In a world where brands crave global reach and social‑media resonance, a front‑running F1 driver is increasingly a walking (and occasionally sliding) multinational ad campaign.


Content Flywheel: From Paddock to PlatformThe F1 narrative now extends far beyond the checkered flag, with streaming series and Hollywood projects turning the paddock into evergreen content. Netflix’s “Drive to Survive,” now heading into its latest season, continues to convert casual viewers into devoted fans by focusing on personalities, pressure, and paddock politics rather than lap times alone.At the same time, a Brad Pitt–led F1 feature film and tech‑driven coverage innovations are expanding the sport’s cultural footprint, pulling in younger and more diverse audiences. For Liberty Media, this ecosystem functions as a flywheel: on‑track drama feeds content, content grows fandom, fandom boosts rights values, and higher rights values fund even better racing.


Why the 2026 Season Looks Like “Growth Guidance”Looking ahead, F1 is guiding more like a fast‑growing media platform than a mature sports league. Management expects earnings per share growth above 20% in both 2026 and 2027, supported by richer media deals, expanding global sponsorships, and a packed race calendar that is increasingly optimized for both local primetime and global streaming windows.With Liberty planning a spin‑off of its Liberty Live stake to simplify its structure, investors could get a cleaner read on F1’s standalone performance, potentially narrowing any “conglomerate discount” embedded in FWONK’s valuation. For a sport built on milliseconds and margins, Formula 1’s business model is now delivering something Wall Street understands very well: recurring, diversified, and accelerating cash flows.

The Sources

Here are the key sources used, listed in numerical order:

  1. F1 revenue surges to $3.9 billion as media rights lead growth – Yahoo Sports
    https://sports.yahoo.com/articles/f1-revenue-surges-3-9-151232089.html[sports.yahoo]​
  2. Formula 1 hits record $3.9bn revenue – News.GP
    https://www.news.gp/en/formula-1-hits-record-3-9bn-revenue[news]​
  3. F1 revenue rises 14% to US$3.87bn in 2025 – SportsPro
    https://www.sportspro.com/news/finance-investment/f1-financial-results-liberty-media-revenue-2025-february-2026/[sportspro]​
  4. Formula 1 shifts into high gear with streaming, spin-off tailwinds – Yahoo Finance / GuruFocus
    https://finance.yahoo.com/news/formula-1-shifts-high-gear-233621722.html[finance.yahoo]​
  5. Formula One Group (FWONK) stock quote and news – Yahoo Finance
    https://sg.finance.yahoo.com/quote/FWONK?p=FWONK[sg.finance.yahoo]​
  6. Formula One Group (FWONK) interactive stock chart – Yahoo Finance (US listing)
    https://uk.finance.yahoo.com/quote/FWONK/chart/[uk.finance.yahoo]​
  7. Formula One Group sees revenue boost from Apple’s ‘F1’ movie – Yahoo Finance
    https://finance.yahoo.com/news/formula-one-group-sees-revenue-163548500.html[finance.yahoo]​
  8. Formula One Group (FWONA): A bull case theory – Yahoo Finance / Substack summary
    https://finance.yahoo.com/news/formula-one-group-fwona-bull-172628354.html[finance.yahoo]​
  9. F1’s deal with Apple questioned despite continued growth – Yahoo Sports
    https://sports.yahoo.com/articles/f1s-deal-apple-questioned-despite-220640541.html[sports.yahoo]​
  10. Top Formula 1 team sponsors for 2026: Oracle, HP, and more – Yahoo Sports
    https://sports.yahoo.com/articles/top-formula-1-team-sponsors-110000025.html[sports.yahoo]​

March 5, 2026 – Dow Takes a Spill While Oil Climbs the Hill: Markets Brace for Impact -( $FIGS $GOVX $INTG $MODD $NVDA $OPEN Rise!)

US stocks sank Thursday as another spike in oil prices and intensifying Iran war fears reignited selling across equities and sent investors back into defensive mode.

Index performance

The Dow Jones Industrial Average dropped more than 784 points, or roughly 1.61% leading declines among the major averages as economically sensitive names bore the brunt of the selloff. The S&P 500 fell around .56% while the tech‑heavy Nasdaq Composite lost about 0.26% giving back a portion of this week’s brief rebound.

Oil shock and macro backdrop

Crude extended its latest surge, with benchmark prices pushing to their highest levels since 2024 as traders priced in a greater risk of supply disruption from the conflict with Iran. Earlier in the week Brent briefly moved above the low‑$80s before stabilizing, but today’s renewed jump revived concerns that higher energy costs will reaccelerate inflation and complicate the Federal Reserve’s path to rate cuts.

Sector and style moves

Energy shares outperformed again as investors sought exposure to producers and refiners that benefit from higher crude prices, extending a run that began when Middle East tensions first flared. In contrast, rate‑ and growth‑sensitive pockets such as high‑multiple tech and longer‑duration assets came under pressure, with many stocks already trading 20% or more below recent highs after this week’s volatility.

Credit, rates, and cross‑asset tone

In the Treasury market, yields that had pushed higher earlier in the week on inflation worries remained elevated, keeping financial conditions tighter even as equities sold off. That backdrop, alongside tumbling risk assets and a bid for perceived havens, underscored a broader flight‑to‑safety tone that left volatility gauges elevated compared with their pre‑conflict levels.

Looking ahead

Traders now turn to upcoming labor data and fresh inflation readings to gauge how much the oil spike will bleed into broader price pressures and whether the Fed can stick to its expected 2026 easing path. With indices having broken down to multi‑month lows earlier this week and bounces proving short‑lived, positioning into any further geopolitical headlines and policy commentary is likely to remain cautious.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Eupraxia Pharmaceuticals (EPRX, $7.94)

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, recently announced the successful closing of its previously announced public offering (the “Offering”) of 7,607,145 common shares of the Company (the “Common Shares”), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$7.00 per Common Share, and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the “Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.000001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$63.2 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering.“We are pleased to complete this financing, allowing us to significantly expand our pipeline, reach several additional development milestones with EP-104GI for eosinophilic esophagitis, and make meaningful progress towards commercial readiness,” said James Helliwell, CEO of Eupraxia. “We appreciate the support from both existing and new investors as we execute our mission and pursue the next phase of growth for Eupraxia.” Cantor and LifeSci Capital acted as joint book-running managers for the Offering. Bloom Burton and Craig-Hallum also acted as co-managers for the Offering. As previously stated, the Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.

Modular Medical (MODD $.2010, +5.85%)

FIGS, Inc. (FIGS, $16.97, +0.0%)

  • FIGS, the direct‑to‑consumer healthcare apparel brand, operates at the intersection of e‑commerce and specialty retail, with a loyal professional customer base and a growing product portfolio. While macro headwinds and digital‑ad volatility have pressured some consumer names, FIGS’ brand equity in the medical community and ongoing product innovation offer levers for renewed growth as conditions normalize.
  • After the close (Feb. 26), FIGS released its fourth quarter and full year 2025 financial results and published a financial highlights presentation on its investor relations highlighting the following: Exceeded Top and Bottom Line Expectations, Grew Q4 2025 Net Revenues 33.0% to a Record $201.9 Million, Achieved Q4 2025 Net Income Margin of 9.2% and Adjusted EBITDA Margin of 13.2% & Plans Low Double-Digit Net Revenues Growth and Margin Expansion in FY 2026. FIGS shares have traded up to $13.74 in the aftermarket today.

GeoVax Labs (GOVX, $1.74, +2.35%)

DoubleVerify (DV, $10.92, +5.62%)

  • DoubleVerify, the leading software platform for digital media measurement, data and analytics, today announced financial results for the fourth quarter and full year ended December 31, 2025 and highlighted the following: Increased 2025 Revenue by 14% Year-over-Year to $748.3 Million, Driven by Global Growth in Social, CTV Measurement, and Programmatic Activation, Achieved 2025 Net Income of $50.7 Million and Adjusted EBITDA of $245.6 Million, representing a 33% Adjusted EBITDA margin, & $300 Million Authorized for Share Repurchases, the Largest Amount in DoubleVerify’s History.

The InterGroup Corporation (INTG, $32.63, +1.12%)

  • InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Serina Therapeutics (SER, $1.57)

  • Serina Therapeutics, a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, announced (Feb. 19) that the first patient has been enrolled in the Company’s Phase 1b registrational trial evaluating. The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina remains on track to initiate dosing during the current quarter, consistent with previously disclosed guidance.

Volato Group, Inc. (SOAR) & M2i Global, Inc. (MTWO)

  • Volato and M2i Global reaffirmed their goal of closing their business combination in the first quarter of 2026, citing steady advancement through SEC review and integration planning as they move toward a combined listing. The deal, originally announced in 2025, will effectively transition Volato from a pure‑play private aviation operator into a diversified platform spanning aviation technology and critical minerals, with M2i shareholders expected to own the majority of the combined entity. Operationally, the partnership is already visible: the two companies recently initiated their first shipment of titanium ore from Western Australia to the United States from Titanium X, underscoring how the critical‑minerals vertical could become a meaningful growth engine as domestic supply‑chain security rises in strategic importance.
  • On Feb. 4, M2i Global,Inc.along with Volato Group, Inc. announced that Titanium X has initiated its first shipment of titanium ore from Western Australia to the U.S. under its collaboration agreement.

NVIDIA (NVDA, $183.34, +.16%)

  • Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.

McDonald’s (MCD, $327.45)

  • Options data around the February 2026 expiries highlight active positioning near the 300–305 strike range, consistent with expectations for steady but not explosive upside from here.
  • In the run-up to World Protein Day on 27th February, McDonald’s India (West & South), owned and operated by Westlife Foodworld, is celebrating Protein Week, reinforcing its leadership in nutrition-led innovation. Making protein more accessible, affordable and customizable, Indian consumers can use the McDonald’s app to explore these nutritious offerings and avail of protein burgers starting at just INR 69. Enhancing this convenience, consumers ordering via McDelivery can also enjoy free delivery on the Protein Plus meal range.

Nokia (NOK, $7.85)

Opendoor (OPEN, $5.18, +6.15%)

The Sources

[1] Stock market today: Dow falls more than 900 points, S&P 500 and … https://finance.yahoo.com/news/live/stock-market-today-dow-falls-more-than-900-points-sp-500-and-nasdaq-slide-as-iran-war-jitters-return-with-another-oil-surge-154559424.html
[2] Dow plunges over 1100 points, S&P 500 and Nasdaq sink as oil … https://finance.yahoo.com/news/live/stock-market-today-dow-plunges-over-1100-points-sp-500-and-nasdaq-sink-as-oil-surges-amid-war-worries-150425235.html
[3] Stock Market News, March 4, 2026: Nasdaq Gains 1.3%, Oil Prices … https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-03-04-2026
[4] Stock markets today: U.S. stocks rebound, oil prices ease https://www.bnnbloomberg.ca/markets/dow-jones/2026/03/04/wall-street-is-mixed-and-oil-prices-stabilize-with-war-in-iran-entering-a-fifth-day/
[5] Stock Market News for Mar 3, 2026 – Yahoo Finance https://finance.yahoo.com/news/stock-market-news-mar-3-142000562.html
[6] Stocks Sink as Crude Oil Surge Rattles Markets – Nasdaq https://www.nasdaq.com/articles/stocks-sink-crude-oil-surge-rattles-markets
[7] Dow falls 1,000 points as oil resumes surge, hitting $80 a barrel amid Iran conflict: Live updates https://www.cnbc.com/2026/03/04/stock-market-today-live-updates-iran-war.html
[8] Yahoo Finance – Stock Market Live, Quotes, Business & Finance News https://finance.yahoo.com
[9] USD Mar 2026 53.000 call (USD260320C00053000) – Yahoo Finance https://finance.yahoo.com/quote/USD260320C00053000/history/
[10] FIVE Mar 2026 175.000 put (FIVE260320P00175000) https://finance.yahoo.com/quote/FIVE260320P00175000/
[11] MAT Mar 2026 5.000 call (MAT260320C00005000) – Yahoo Finance https://finance.yahoo.com/quote/MAT260320C00005000/history/
[12] I:SPX Mar 2026 Weekly 6175.000 (SPXW260303P06175000) https://finance.yahoo.com/quote/SPXW260303P06175000/history/
[13] I:SPX Mar 2026 Weekly 6805.000 (SPXW260317C06805000) https://finance.yahoo.com/quote/SPXW260317C06805000/
[14] Dow falls 400 points, oil spike moderates amid Middle East tensions https://www.foxbusiness.com/markets/us-stocks-march-3-2026-dow-falls-oil-spikes-middle-east-tensions
[15] V Mar 2026 345.000 call (V260313C00345000) – Yahoo Finance https://finance.yahoo.com/quote/V260313C00345000/chart/

FDA’s New Bonus Plan: Can Cash Tips Speed Up Drug Reviews Without Cutting Corners? -( $IBB $XBI )

The U.S. Food and Drug Administration (FDA) is reportedly rolling out a new cash‑bonus program to reward drug reviewers who deliver high‑quality decisions ahead of schedule, a move pitched as both a modernization of government HR and a lifeline for an agency straining under mounting workloads and staff attrition.

New Incentives at a Stressed Regulator

Under the pilot, FDA scientists who complete reviews before internal targets and user‑fee performance goals will be eligible for quarterly bonuses worth several thousand dollars, with payouts tied to both “weighted time savings” and documented work quality. The effort follows years of rising application volume and a reported loss of roughly one‑fifth of personnel in some drug review divisions, creating what officials now openly describe as “critical workforce challenges.”

Commissioner Marty Makary outlined the initiative to staff as a time‑limited pilot, with the first bonus payments expected around late summer if internal milestones are met. The initiative layers individual incentives on top of long‑standing industry‑funded user‑fee programs, which already commit the agency to ambitious review timelines but historically have not rewarded front‑line reviewers personally for beating the clock.

How the Bonus Plan Works

The bonus formula centers on “weighted time savings,” which credits reviewers for accelerating decisions on more complex or clinically significant applications, rather than simply rewarding the fastest file off the pile. Internal materials describe quarterly bonuses for staff who deliver high‑quality, on‑time or early decisions, with awards scaled by workload, case complexity, and supervisor ratings, in a structure reminiscent of federal retention incentives that can reach a notable share of base pay.

Importantly, FDA officials stress that statutory standards for safety and efficacy remain unchanged and that no product should be approved before the scientific work is complete, even as the agency pushes to reduce the “time‑to‑decision” for new drug applications and biologics license applications. The pilot also excludes staff who are not directly involved in review work, underscoring its targeted aim: keeping seasoned regulatory scientists in their chairs—and focused—through a mix of mission and money.

Workforce Medicine for a Talent Squeeze

Behind the bureaucratic language is a simple diagnosis: the FDA has been losing experienced reviewers while the biotech pipeline gets denser and more complex, from gene therapies to GLP‑1s and rare‑disease treatments. Industry‑backed user‑fee programs such as PDUFA and MDUFA were designed to fund additional staff and set transparent review deadlines, but recent staffing cuts and funding uncertainties have put pressure on the agency’s ability to meet those goals consistently.

By dangling quarterly cash instead of just another framed certificate, the FDA is borrowing a page from the private sector playbook to retain specialized talent that can be difficult and costly to replace. The move also acknowledges a political reality: it may be easier to tweak incentives inside existing funding constraints than to secure large, permanent increases in appropriations from a divided Congress.

Speed, Safety, and a Touch of Skepticism

Not surprisingly, the idea of paying regulators to be faster has prompted questions about whether speed could come at the expense of safety. Advocates of the program counter that bonuses are explicitly tied to high‑quality reviews and that user‑fee goals already contemplate that some applications will legitimately run past target dates when the science demands more scrutiny.

Still, watchdogs note that the agency will have to demonstrate over the next two to three years that any reduction in review times does not coincide with a rise in post‑market safety issues, a metric analysts are already watching closely. If the pilot delivers faster approvals without compromising outcomes, it could become a template for other backlogged federal shops—from patent examiners to securities lawyers—where time really is money.

What It Means for Pharma, Patients, and Policy

For drug developers, every month shaved off the regulatory calendar can translate into millions of dollars in additional revenue and earlier patient access, raising the stakes for getting submissions “review‑ready” on day one. Legal, regulatory, and clinical teams may need to match the FDA’s new tempo, tightening their own response times to information requests as reviewers become more motivated to keep files moving.

Patients’ groups, meanwhile, are likely to welcome anything that shortens the wait for promising therapies, so long as confidence in the agency’s safety record holds. And on Capitol Hill, the bonus program could become an unexpected data point in the broader debate over how to fund a 21st‑century FDA: if relatively modest, performance‑based incentives can meaningfully improve throughput, lawmakers may find themselves rethinking what a “lean but effective” regulator really looks like.

The Sources


[1] US FDA to offer bonuses to staff for faster drug reviews, source says https://www.reuters.com/legal/litigation/us-fda-offer-bonuses-speed-up-drug-reviews-bloomberg-news-reports-2026-02-26/
[2] FDA to Give Staff Bonuses for Speeding Up Drug Reviews https://www.bloomberg.com/news/articles/2026-02-26/fda-to-give-staff-bonuses-for-speeding-up-drug-reviews
[3] FDA Proposal Offers Quarterly Bonuses for Faster Drug Reviews https://www.medindia.net/news/fda-proposal-offers-quarterly-bonuses-for-faster-drug-reviews-222568-1.htm
[4] FDA To Offer Cash Bonuses for Faster Drug Reviews – eMPR.com https://www.empr.com/news/fda-to-offer-cash-bonuses-for-faster-drug-reviews/
[5] FDA To Offer Cash Bonuses for Faster Drug Reviews https://www.usnews.com/news/health-news/articles/2026-03-02/fda-to-offer-cash-bonuses-for-faster-drug-reviews
[6] FDA’s User Fee Programs at a Crossroads – Biotech Briefings https://biotechbriefings.gibsondunn.com/fdas-user-fee-programs-at-a-crossroads-user-fee-deadlines-and-funding-at-risk/
[7] FDA to offer bonus payments to staffers who complete speedy drug … https://firstwordpharma.com/story/7122344
[8] FDA: User Fees Explained https://www.fda.gov/industry/fda-user-fee-programs/fda-user-fees-explained
[9] FDA-TRACK: Medical Device User Fee Amendments (MDUFA … https://www.fda.gov/about-fda/fda-track-agency-wide-program-performance/fda-track-medical-device-user-fee-amendments-mdufa-performance-reports
[10] FDA To Offer Its Workers Monetary Incentives For Faster Drug Reviews https://kffhealthnews.org/morning-breakout/fda-to-offer-its-workers-monetary-incentives-for-faster-drug-reviews/
[11] Fact Sheet: Retention Incentive Payment and Termination Calculations https://www.opm.gov/policy-data-oversight/pay-leave/recruitment-relocation-retention-incentives/fact-sheets/retention-incentive-payment-and-termination-calculations/
[12] FDA Launches Staff Bonuses for Faster Drug Reviews https://getlegalbrief.com/story/fda-bonus-payments-speedy-drug-reviews
[13] US FDA to offer bonuses to staff for faster drug reviews, Bloomberg … https://wncy.com/2026/02/26/us-fda-to-offer-bonuses-to-staff-for-faster-drug-reviews-bloomberg-news-reports/
[14] FDA to offer cash bonuses for faster drug reviews – Medical Xpress https://medicalxpress.com/news/2026-03-fda-cash-bonuses-faster-drug.html
[15] FDA to offer bonus payments to staffers who complete speedy drug … https://www.yahoo.com/news/articles/fda-offer-bonus-payments-staffers-214012867.html

Oracle Cuts Thousands of Jobs to Build AI Data Centers: Firing on All Cloud Cylinders -( $ORCL $NVDA $SPY )

Oracle’s (ORCL) latest round of layoffs is less a retreat than a high‑stakes reshuffling for the age of artificial intelligence, as the software giant trades payroll for power plants in a bid to secure its place in the cloud big leagues.

A Cloud Challenger Writes a Costly New Chapter

Oracle has spent the past few years recasting itself from legacy database stalwart to ambitious cloud and AI infrastructure contender, backed by a marquee, multiyear compute deal with OpenAI and other hyperscale customers. The company is now planning to cut thousands of jobs as early as this month, a move that follows warnings from Wall Street analysts that total reductions could reach 20,000 to 30,000 roles, or roughly a tenth of its global workforce.

The stated goal is not a slimmer story, but a richer one: by trimming headcount, Oracle aims to unlock an estimated 8 to 10 billion dollars in annual cash flow to help fund what TD Cowen pegs as roughly 156 billion dollars in AI‑focused data‑center capital expenditures over the coming years. For a company historically known for squeezing software maintenance margins, this is a different kind of discipline—closer to industrial policy than IT housekeeping.

When Payroll Meets Power Bills

Behind the layoffs is an uncomfortable arithmetic that’s becoming familiar across Big Tech: as capital spending on AI infrastructure climbs, something else has to give. Oracle’s planned data‑center expansion—built around millions of GPUs, rising borrowing costs, and banks that have grown notably shy about funding long‑dated AI projects—has pushed the company into a financing corner where cutting jobs looks cheaper than paying higher interest.

Analysts estimate Oracle needs to raise 45 to 50 billion dollars this year alone to keep its cloud build‑out on schedule, even as lenders have roughly doubled the interest rate premiums they charge for related project financing since last fall. In that light, shrinking the payroll becomes less a commentary on engineering prowess and more a hedge against the bond market’s sense of humor.

Restructuring for the AI Era

The current plan builds on what Oracle flagged months ago: its largest restructuring effort to date, with up to 1‑plus billion dollars in charges, including severance for departing employees. The company already cut an estimated 10,000 roles in late 2025 and has told staff it is reassessing many open positions in its cloud division, effectively pausing or slowing hiring just as demand for AI compute soars.

Some of the affected positions sit in areas Oracle expects to shrink as AI tools take over more routine work, underscoring a blunt reality of the current cycle: the same automation investors cheer in earnings calls increasingly shows up as a line item in workforce reductions. Yet Oracle is still carrying roughly 162,000 employees worldwide, giving it room to reassign talent toward higher‑growth businesses even as it tightens overall headcount.

Betting Big on AI Infrastructure

If the layoffs are the most visible headline, the main plot is Oracle’s conviction that AI data centers will define the next decade of enterprise tech. The company is racing to add capacity for customers ranging from OpenAI and xAI to social and semiconductor heavyweights, positioning its cloud as a differentiated high‑performance alternative in a market dominated by Amazon, Microsoft, and Google.

To do that, Oracle is not just trimming staff; it is also exploring asset sales, including a potential divestiture of its Cerner healthcare unit, acquired for 28.3 billion dollars in 2022, to further ease the funding strain. In effect, Oracle is treating non‑core businesses and lower‑priority roles as internal financing instruments—redeployed to bankroll data halls, fiber, and racks of AI accelerators that it hopes will pay dividends well beyond the next earnings print.

A Difficult Edit With an Optimistic Ending

For employees facing uncertainty, this chapter reads painfully personal; for investors, it’s a test of whether Oracle can convert aggressive capex into durable cloud share rather than just eye‑catching headlines. Still, there is a clear strategic through‑line: consolidate around AI infrastructure, trade short‑term comfort for long‑term positioning, and move quickly while hyperscale demand is effectively booked years in advance.

If Oracle’s wager pays off, the company will emerge leaner, more focused, and wired into some of the largest AI workloads on the planet—proof that, in today’s market, the most consequential corporate turnarounds are being drafted not in corner offices, but in data‑center blueprints and power‑usage curves. What angle or audience are you targeting for this piece—general investors, tech workers, or enterprise CIOs?

The Sources


[1] Oracle Plans Thousands of Job Cuts in Face of AI Cash Crunch https://finance.yahoo.com/news/oracle-plans-thousands-job-cuts-180243222.html
[2] Oracle may slash up to 30,000 jobs amid AI data centre funding … https://finance.yahoo.com/news/oracle-may-slash-30-000-114418881.html
[3] Oracle plans thousands of job cuts as data center costs rise … https://finance.yahoo.com/news/oracle-plans-thousands-job-cuts-181330521.html
[4] Oracle Layoffs: Oracle plans to slash headcount by 20,000-30,000 to … https://economictimes.com/tech/technology/oracle-plans-to-slash-headcount-by-20000-30000-to-pay-for-ai-data-centres-report/articleshow/127852064.cms
[5] Oracle Plans To Lay Off 20,000 To 30,000 Employees: Report – NDTV https://www.ndtv.com/world-news/oracle-plans-to-lay-off-20-000-to-30-000-employees-report-10930781
[6] Oracle Plans Large Layoffs To Fund Data Centers | Let’s Data Science https://www.letsdatascience.com/news/oracle-plans-large-layoffs-to-fund-data-centers-5f1594d2
[7] Analyst Warns Oracle Could Cut Up to 30000… – Metaintro https://www.metaintro.com/blog/oracle-job-cuts-ai-expansion
[8] Oracle may slash up to 30,000 jobs to fund AI data-center expansion … https://www.cio.com/article/4125103/oracle-may-slash-up-to-30000-jobs-to-fund-ai-data-center-expansion-as-us-banks-retreat.html
[9] Oracle Cuts 30,000 Jobs to Fund $156B AI Infrastructure Buildout https://www.linkedin.com/posts/clintonwhouse_oracle-amd-meta-activity-7425542697718988800-ljIY
[10] Oracle reported cutting thousands of jobs amid data center growth https://au.finance.yahoo.com/news/oracle-reported-cutting-thousands-jobs-184215583.html
[11] 30,000 Layoffs Could Soon Hit at Oracle. What Does That Mean for … https://finance.yahoo.com/news/30-000-layoffs-could-soon-194659263.html
[12] Oracle is contemplating cutting nearly 20000-30000 jobs and selling … https://www.facebook.com/cnbctv18india/posts/layoffs2026-oracle-is-contemplating-cutting-nearly-20000-30000-jobs-and-selling-/1380695420757886/
[13] Oracle reportedly plans to lay off thousands of employees https://finance.yahoo.com/video/oracle-reportedly-plans-lay-off-193212079.html
[14] Oracle Lays Off 30,000 Amid AI Infrastructure Spending Pressure https://www.linkedin.com/posts/rathanuday_oracle-openai-techlayoffs-activity-7424170002012102656-Ljyv
[15] Why is Oracle planning to slash 30000 jobs? | Data centres – YouTube https://www.youtube.com/watch?v=SH4_CTsocd8

When AI Chips Order Room Service: Broadcom, Nvidia and Nokia Rewire the Data‑Center Hotel -( $AVGO $META $NOK $NVDA )

Broadcom’s (AVGO) chief executive is sounding less like a cautious chipmaker and more like the maître d’ of a very exclusive AI banquet, calmly assuring investors that the kitchen can handle the rush. In this rapidly evolving feast, Nvidia (NVDA) is serving the appetizers, Broadcom is quietly taking over the main course, and Nokia (NOK) is busy rebuilding the dining room so the whole operation doesn’t collapse under the weight of data.

Broadcom’s AI Bet Moves From Hype To Backlog

The latest message from Broadcom’s leadership is simple: the AI chip boom is no longer a theory, it’s a booked business. The company has disclosed an enormous multiyear pipeline for custom AI accelerators, talking openly about revenue potential in the tens of billions of dollars from a small group of hyperscale cloud customers building their own silicon.

CEO Hock Tan has framed AI semiconductors as a market that is set to outgrow the non‑AI chip universe, positioning Broadcom as the quiet power broker behind the data‑center curtain. Where Nvidia largely sells branded processors, Broadcom specializes in bespoke “XPUs” and networking silicon that let the biggest platforms reduce dependence on off‑the‑shelf GPUs while keeping their own AI ambitions closely held.

Nvidia: Still The Reference Name In AI Silicon

For now, Nvidia remains the name that defines the AI chip cycle, and its recent guidance suggests that the spending wave is still building rather than breaking. The company has guided revenue above expectations on the back of strong demand for its data‑center processors, noting that it has secured enough inventory and capacity to support customers through multiple quarters.

Big Tech’s capital‑expenditure plans underscore why Nvidia’s order book still looks more like a waiting list than a sales pipeline. Hyperscalers such as Alphabet, Microsoft, Amazon and Meta (META) have collectively signaled hundreds of billions of dollars in 2026 capex, with the bulk earmarked for data centers and AI‑centric compute. Even as new competitors emerge, from AMD to in‑house chips at cloud platforms, Nvidia’s data‑center business has broadened beyond a handful of customers, suggesting that AI demand is diffusing across industries rather than drying up.

Nokia Builds The AI‑Native Network

While Broadcom and Nvidia compete to power the brains of AI, Nokia is methodically redesigning the nervous system that connects them. The telecom stalwart has laid out a strategy for AI‑driven, highly autonomous networks, arguing that AI is no longer a feature bolted onto infrastructure but the defining workload of the “network economy.”

Through partnerships that include work with Nvidia on AI‑RAN concepts and trials of software running on Nvidia platforms, Nokia is using data‑center‑class AI chips to modernize radio access and edge networks. A recently announced exclusive deal to supply AI‑ready networking gear for Telefónica’s edge network highlights how the company aims to sit at the crossroads of cloud, telecom and AI workloads. Nokia’s ambition is to turn the network into a distributed fabric of intelligence, where automation and sensing are built into the radio layer rather than treated as expensive afterthoughts.

The New AI Stack: From Silicon To Self‑Driving Networks

Taken together, Broadcom, Nvidia and Nokia offer a useful blueprint for what the late‑cycle AI stack really looks like. Nvidia’s processors remain the default option for training and running large models, providing the high‑performance compute that keeps the current wave of AI applications possible. Broadcom, meanwhile, is capitalizing on the desire of hyperscalers to control their own destiny with custom accelerators and networking silicon, turning AI demand into long‑dated backlog rather than a fleeting fad.finance.yahoo+6

Nokia slots into this picture as the industrial‑grade plumber of the networked AI era, embedding automation and AI‑ready capabilities deep into 5G and future radio architectures. If Nvidia is selling the shovels in this digital gold rush and Broadcom is machining custom tools for the biggest miners, Nokia is quietly reinforcing the tunnels so the whole operation can scale without a safety notice from the regulators.

What It Means For Investors Watching The “Late” AI Cycle

For investors wondering whether the AI trade has already peaked, the signals from this trio suggest a more nuanced story. Broadcom’s climbing AI backlog, Nvidia’s confident guidance and Nokia’s deepening role in AI‑native networking all point to a market that is broadening in scope even as headlines warn of hype.

The center of gravity is shifting from pure GPU headlines to a more complete stack: custom accelerators, specialized networking and autonomous infrastructure. For readers looking beyond the first wave of AI winners, that may be the most important development of all—because when the market stops asking “who sells the chips?” and starts asking “who makes all of this actually work together?”, companies like Broadcom, Nvidia and Nokia look less like a story about a boom and more like the foundation of a new, and still unfolding, AI economy.

The Sources

  1. Broadcom CEO Sees AI Chip Sales Topping $100 Billion in 2027 – Yahoo Finance
    https://finance.yahoo.com/news/broadcom-ceo-sees-ai-chip-001047450.html[finance.yahoo]​
  2. Broadcom’s AI Surge Tests Valuation as Custom Chips and Telco Deals Pile Up – Yahoo Finance
    https://finance.yahoo.com/news/broadcom-ai-surge-tests-valuation-031459134.html[finance.yahoo]​
  3. Broadcom CEO Pay Jumps to $205.3 Million on AI Push – Yahoo Finance
    https://finance.yahoo.com/news/broadcom-ceo-pay-jumps-205-132515489.html[finance.yahoo]​
  4. Broadcom Stock Pops on AI Chip–Driven Q1 Earnings Beat – Yahoo Finance (video/article)
    https://finance.yahoo.com/video/broadcom-stock-pops-ai-chip-shares-165129959.html[finance.yahoo]​
  5. Broadcom Ships New AI Chip as Shares Jumped 49% Last Year – Yahoo Finance
    https://finance.yahoo.com/news/broadcom-ships-ai-chip-shares-165129959.html[finance.yahoo]​
  6. Broadcom Is an AI Stock You Want to Own in Long Term: Strategist – Yahoo Finance
    https://finance.yahoo.com/video/broadcom-ai-stock-want-own-215207219.html[finance.yahoo]​
  7. Nokia Wins Exclusive AI Network Deal With Telefónica – Yahoo Finance
    https://finance.yahoo.com/news/nokia-wins-exclusive-ai-network-213014237.html[finance.yahoo]​
  8. Nokia to Deploy Network Solutions for Telefónica’s AI Data Centres Across Spain – Economic Times Telecom
    https://telecom.economictimes.indiatimes.com/news/telecom-equipment/nokia-wins-multi-year-deal-to-power-telefonicas-ai-edge-data-centres-across-spain/[telecom.economictimes.indiatimes]​
  9. Nokia Partners with Telefónica to Enhance Digital Infrastructure – Intellectia
    https://intellectia.ai/news/etf/nokia-partners-with-telefnica-to-enhance-digital-infrastructure[intellectia]​
  10. Nvidia Forecasts Upbeat Sales on AI Chip Demand – The Star
    https://www.thestar.com.my/business/business-news/2026/02/27/nvidia-forecasts-upbeat-sales-on-ai-chip-demand[thestar.com]​
  11. Nvidia Forecasts Upbeat Quarterly Sales as AI Boosts Chip Demand – WMBDradio
    https://wmbdradio.com/2026/02/25/nvidia-forecasts-upbeat-quarterly-sales-as-ai-boosts-chip-demand/[wmbdradio]​
  12. Nvidia Forecasts Upbeat Sales on AI Chip Demand, Talks Up Long-Term Prospects – Economic Times
    https://economictimes.com/tech/technology/nvidia-forecasts-upbeat-sales-on-ai-chip-demand-talks-up-long-term-prospects/articleshow/[economictimes]​

Insulin Pumps Have a Moment: Why Insulet Is Growing Like a Tech Stock, Not a Medical Device -( $PODD $TNDM $MODD )

Insulin pumps are having a moment, and this time it is not just Wall Street that is impressed—it is patients, payers, and, increasingly, competitors playing catch‑up.

Insulet’s Growth Streak Enters Double Digits

Insulet (PODD) closed 2025 like a company that never got the memo about “mature medtech,” delivering approximately 31% revenue growth in the fourth quarter to about 784 million dollars and crossing roughly 2.7 billion dollars for the full year. That marked its 10th consecutive year of more than 20% constant‑currency revenue expansion, an achievement more typical of hot software names than a maker of wearable insulin pumps.

The company’s Omnipod franchise did most of the heavy lifting, with Pod revenue growing in the low‑30% range and essentially accounting for the entire topline. Management highlighted another year of record new customer starts as patients continued migrating from multiple daily injections to automated delivery, a structural shift that still has considerable runway.

Margin Muscle in a Competitive Market

Insulet did not just grow; it grew with discipline. Gross margin in the fourth quarter expanded to roughly 72.5%, up about 40 basis points year over year, while full‑year gross margin finished around 71.6%, nearly 180 basis points higher than 2024. Operating income climbed to about 146 million dollars in Q4, or roughly 18.7% of revenue, with adjusted operating income moving in lockstep and advancing 30 to 40 basis points.investor.insulet+3

For 2025 as a whole, Insulet generated operating income in the mid‑400‑million‑dollar range and lifted operating margin by more than two percentage points, even as it invested in expanding capacity, innovation, and commercial reach. Free cash flow topped roughly 375 million dollars, offering investors the comforting reminder that rapid growth and cash generation are not mutually exclusive concepts.

Diabetes Care: From Niche to Strategic Asset

Insulet’s sustained growth says as much about the diabetes technology market as it does about the company. Management pointed to continued adoption of automated insulin delivery systems as physicians grow more comfortable prescribing pumps for a broader swath of patients, including those earlier in the disease course. With U.S. revenue growing in the high‑20% range and international sales advancing at an even faster clip in the fourth quarter, Omnipod is increasingly a global story rather than a North American niche. The U.S. market size is now at +27 million people with diabetes, where 4.88 million require daily insulin (2M Type 1, 2.88M Type 2). Only 20% of insulin dependent people with diabetes use a pump for insulin delivery. 80% rely on multiple daily injections (MDI).

Analysts now expect Insulet’s revenue to grow around the high‑teens to roughly 20% over the next year, slower than the recent breakneck pace but still robust for a company already above 2.5 billion dollars in sales. That leaves Insulet in the enviable position of arguing not whether it can grow, but whether it chooses to prioritize margin expansion, share gains, or both—an executive‑level version of having to pick just one dessert.

Modular Medical: The Challenger at the Gate

If Insulet represents the established growth franchise, Modular Medical (NASDAQ: MODD) is the challenger trying to re‑write the script on affordability and access. The company recently announced a 12 million dollar public offering priced at a premium to market, a notable show of confidence for a small‑cap medtech name in a still‑selective funding environment. The deal, led by Maxim Group, includes immediately exercisable warrants with a five‑year term, giving investors both capital appreciation potential and time to see the commercial story unfold.

Modular Medical’s pitch is elegantly simple: take lessons learned from prior pump platforms and engineer a system aimed at lower cost and easier use, broadening the market beyond today’s more complex devices. The company’s founder, Paul DiPerna, previously founded Tandem Diabetes (TNDM) and designed its t:slim pump, giving this new venture a pedigree that has not gone unnoticed among diabetes‑tech watchers. For a market where many patients still rely on injections for cost or usability reasons, a lower‑friction pump could be more than a niche—it could be an on‑ramp. The U.S. market size is now at +27 million people with diabetes, where 4.88 million require daily insulin (2M Type 1, 2.88M Type 2). Only 20% of insulin dependent people with diabetes use a pump for insulin delivery. 80% rely on multiple daily injections (MDI). HCPs fairly consistently indicated that about 25% of their MDI population are “almost pumpers”, meaning
that they have considered going on a pump, understand pump therapy benefits, but want something
simpler that doesn’t have all the “bells and whistles’, which is estimated to be ~$3 billion US market opportunity.

Two Paths, One Market: Insulet vs. Modular Medical

Investors now find themselves watching two very different approaches to the same problem: how to deliver insulin more effectively, with fewer trade‑offs for patients and payers.

CompanyCore focus2025/Recent scaleStrategic lever
Insulet (PODD)Tubeless Omnipod AID systems~2.7B dollars revenue, 31% growth Premium, high‑growth global platform
Modular MedicalLower‑cost, simplified pump platformDevelopment‑stage, raised 12M dollars this weekAffordability, ease of use

Insulet enjoys the advantages of scale, brand recognition, and a decade‑long track record of 20%‑plus growth, but it must continue innovating as competition intensifies and payers scrutinize every incremental dollar. Modular Medical (MODD), by contrast, is betting that a leaner design via their insulin pump called Pivot and a focus on lower cost could open new segments of the market—provided it can execute on manufacturing, regulatory milestones, and commercial rollout.

For Wall Street, the setup is familiar: a market leader proving the category’s durability and a newcomer seeking to expand the pie rather than simply slicing it thinner. For patients, it is a rare case where investors’ enthusiasm and clinical needs are aligned; more options in insulin delivery typically translate to better matches for individual lifestyles and budgets.

Outlook: An Expanding Field, Not a Zero‑Sum Game

Looking ahead, Insulet has guided to continued double‑digit growth, underpinned by ongoing conversion from injections, expansion into international markets, and further penetration of automated insulin delivery in both Type 1 and select Type 2 populations. The company’s strengthening balance sheet and rising free cash flow give it ample flexibility to invest in R&D, capacity, and potential partnerships, all while nudging margins higher over time.

Modular Medical (MODD), for its part, now has fresh capital and a longer runway to pursue its mission of making pump therapy more attainable. If the company can translate engineering expertise into a commercially viable, lower‑cost product, it may help expand the overall pump‑eligible population rather than simply vie for share within it—a scenario where the leader and the upstart both stand to benefit.

In a market long defined by trade‑offs—control versus convenience, innovation versus cost—the emerging narrative in diabetes tech is refreshingly constructive. Insulet is proving that scale and innovation can coexist, while Modular Medical (MODD) is trying to ensure that innovation does not become a luxury good, and that might be the kind of competition patients would not mind seeing a lot more of.

The Sources

Here is a clean, numbered source list with live links:

  1. Insulet Reports Fourth Quarter and Full Year 2025 Results (Insulet IR)
    https://investor.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx[investor.insulet]​
  2. Insulet Reports Fourth Quarter and Full Year 2025 Results (Yahoo Finance syndication)
    https://finance.yahoo.com/news/insulet-reports-fourth-quarter-full-120000955.html[finance.yahoo]​
  3. Insulet Corporation Q4 2025 Earnings Call Summary
    https://finance.yahoo.com/news/insulet-corporation-q4-2025-earnings-133000560.html[finance.yahoo]​
  4. Insulet Corp (PODD) Q4 2025 Earnings Call Highlights
    https://finance.yahoo.com/news/insulet-corp-podd-q4-2025-190048367.html[finance.yahoo]​
  5. Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales
    https://finance.yahoo.com/news/insulet-nasdaq-podd-surprises-q4-120738996.html[finance.yahoo]​
  6. Insulet Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
    https://www.marketscreener.com/news/insulet-corporation-reports-earnings-results-for-the-fourth-quarter-and-full-year-ended-dece-xxxx[marketscreener]​
  7. Insulet Q4 2025 Slides: Revenue Soars 31%, Stock Jumps on Strong 2026 Outlook
    https://www.investing.com/news/company-news/insulet-q4-2025-slides-revenue-soars-31-stock-jumps-on-strong-2026-outlook-93CH-4511[investing]​
  8. Insulet Stock Rises Before Hours on Q4 Beats, 31% Sales Growth
    https://www.drugdeliverybusiness.com/insulet-q4-2025-beats-stock-growth/[drugdeliverybusiness]​
  9. Insulet Boosts Buyback, Posts 31% 2025 Revenue Growth
    https://www.stocktitan.net/sec-filings/PODD/8-k-insulet-corp-reports-material-event-8b015c630092.html[stocktitan]​
  10. Modular Medical Announces 12.0 Million Public Offering Priced at a Premium to Market
    https://finance.yahoo.com/news/modular-medical-announces-12-0-142700002.html[finance.yahoo]​
  11. Modular Medical Announces 12.0 Million Public Offering Priced at a Premium to Market (press release host)
    https://www.biospace.com/press-releases/modular-medical-announces-12-0-million-public-offering-priced-at-a-premium-to-market[biospace]​
  12. Modular Medical Prices 12M Stock and Warrant Sale
    https://www.stocktitan.net/news/MODD/modular-medical-announces-12-0-million-public-offering-priced-at-a-94hlmxlvuulh.html[stocktitan]​
  13. Modular Medical Begins Production of Insulin Pump Components
    https://www.streetinsider.com/Corporate+News/Modular+Medical+begins+production+of+insulin+pump+components/25943724.html[streetinsider]​
  14. Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump
    https://nationaltoday.com/us/ca/san-diego/news/2026/02/05/modular-medical-achieves-key-manufacturing-milestone-for-pivot-tubeless-insulin-patch-pump[nationaltoday]​

March 4, 2026 – Markets Hold Their Nerve: Iran Blinks, Bitcoin Winks, and Bulls Tiptoe Back In -( $ASNS $BTC $DV $EPRX $FIGS $GOVX $INTG $MODD $MRNA $NOK $NVDA Rise!)

US stocks rebounded on Wednesday, March 4, 2026, as easing fears around the Iran conflict and steadier oil prices helped buyers step back in, while Bitcoin extended its latest surge.

Index performance

The major US benchmarks climbed, recapturing a chunk of the prior session’s losses tied to Middle East tensions.finance.yahoo+2

  • The S&P 500 rose about 0.78%, closing near 6,869.50 after trading around 6,877 intraday.
  • The Dow Jones Industrial Average added roughly 0.49%, finishing around 48,739.41.
  • The Nasdaq Composite outperformed with a gain of about 1.29%, ending at 22,807.48 as growth and tech bounced.
  • The Russell 2000 advanced roughly 1.06%, signaling renewed appetite for smaller caps after recent underperformance.

This rebound came after a choppy stretch in which war headlines had driven sharp intraday swings and a notable pullback in the Dow.

Macro and geopolitics

Traders remained focused on developments in the Iran conflict, but the tone shifted as hopes for at least a pause in escalation nudged volatility lower. Oil, which had spiked on supply-risk fears, stabilized on Wednesday; Crude finished the day roughly flat around $76.16/bbl per barrel, removing an immediate pressure point for equities.

Better‑than‑feared US economic readings and still‑solid corporate commentary helped offset geopolitical anxiety, reinforcing the narrative that growth remains intact even as markets digest higher energy volatility. US private employers added 63k in February, which exceeded expectations according to the private payroll processor ADP.

Sectors and themes

Risk appetite rotated back toward growth, with technology and communication-services names leading the Nasdaq’s rebound. Defense and energy, which had already benefited from prior days’ tension‑driven flows, held firm as crude prices leveled out, while more defensive areas like utilities and staples lagged the broader move higher. Smaller caps’ outperformance hinted at a modest revival of domestic cyclical plays, though index-level data show the S&P 500 is still fractionally lower week‑to‑date, underscoring how fragile sentiment remains.

Crypto and Bitcoin

In digital assets, Bitcoin (BTC) pushed higher, trading back above the high‑$60,000s to low‑$70,000s range as traders leaned into the idea that institutional demand and ETF inflows could sustain the rally. The move comes against a backdrop of mixed signals: on-chain and price‑trend gauges remain cautious after a sharp pullback over the past month, even as some strategists highlight upside scenarios into the $100,000‑plus area if current inflows persist. Crypto’s strength added to the day’s broader “risk‑on” tone, with Bitcoin’s rebound standing in contrast to the defensive posture that dominated when Middle East headlines first hit earlier in the week.

Big picture for investors

Despite Wednesday’s relief rally, the S&P 500 and Dow are only roughly flat to slightly lower for the week, a reminder that geopolitical risk and headline‑driven swings remain central to the tape. For now, the market appears to be in a headline‑sensitive holding pattern: dips tied to Iran and oil shocks are drawing buyers, but sustained upside will likely hinge on clearer evidence that the conflict is contained and that earnings can absorb higher energy and funding costs.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Eupraxia Pharmaceuticals (EPRX, $8.18, +2%)

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, recently announced the successful closing of its previously announced public offering (the “Offering”) of 7,607,145 common shares of the Company (the “Common Shares”), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$7.00 per Common Share, and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the “Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.000001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$63.2 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering.“We are pleased to complete this financing, allowing us to significantly expand our pipeline, reach several additional development milestones with EP-104GI for eosinophilic esophagitis, and make meaningful progress towards commercial readiness,” said James Helliwell, CEO of Eupraxia. “We appreciate the support from both existing and new investors as we execute our mission and pursue the next phase of growth for Eupraxia.” Cantor and LifeSci Capital acted as joint book-running managers for the Offering. Bloom Burton and Craig-Hallum also acted as co-managers for the Offering. As previously stated, the Company intends to use the net proceeds from the Offering primarily for the continued advancement of EP-104GI for Eosinophilic Esophagitis, including the completion of ongoing preclinical studies, and Phase 2 clinical trials, preparations for a Phase 3 clinical trial including the related regulatory submissions, and manufacturing activities, and to undertake the necessary commercial/market development activities to prepare for the eventual product launch. The Company also intends to use a portion of the proceeds to accelerate and expand its plans to pursue clinical studies with EP-104GI in multiple additional gastrointestinal indications, including in esophageal strictures and fibrostenotic Crohn’s disease. A portion of the proceeds will be allocated to research and development of additional pipeline candidates, business development initiatives, and general corporate purposes, which may include but are not limited to employee salaries, working capital, leases for facilities, administrative expenses, and capital expenditures. The Company may also use a portion of the proceeds to expand its intellectual property portfolio and strengthen its corporate infrastructure to support future growth.

Modular Medical (MODD $.1899, +13.04%)

FIGS, Inc. (FIGS, $16.967, +.12%)

  • FIGS, the direct‑to‑consumer healthcare apparel brand, operates at the intersection of e‑commerce and specialty retail, with a loyal professional customer base and a growing product portfolio. While macro headwinds and digital‑ad volatility have pressured some consumer names, FIGS’ brand equity in the medical community and ongoing product innovation offer levers for renewed growth as conditions normalize.
  • After the close (Feb. 26), FIGS released its fourth quarter and full year 2025 financial results and published a financial highlights presentation on its investor relations highlighting the following: Exceeded Top and Bottom Line Expectations, Grew Q4 2025 Net Revenues 33.0% to a Record $201.9 Million, Achieved Q4 2025 Net Income Margin of 9.2% and Adjusted EBITDA Margin of 13.2% & Plans Low Double-Digit Net Revenues Growth and Margin Expansion in FY 2026. FIGS shares have traded up to $13.74 in the aftermarket today.

GeoVax Labs (GOVX, $1.71, +8,92%)

DoubleVerify (DV, $10.34, +1.77%)

  • DoubleVerify, the leading software platform for digital media measurement, data and analytics, today announced financial results for the fourth quarter and full year ended December 31, 2025 and highlighted the following: Increased 2025 Revenue by 14% Year-over-Year to $748.3 Million, Driven by Global Growth in Social, CTV Measurement, and Programmatic Activation, Achieved 2025 Net Income of $50.7 Million and Adjusted EBITDA of $245.6 Million, representing a 33% Adjusted EBITDA margin, & $300 Million Authorized for Share Repurchases, the Largest Amount in DoubleVerify’s History.

The InterGroup Corporation (INTG, $32.27, +3.03%)

  • InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Serina Therapeutics (SER, $1.67)

  • Serina Therapeutics, a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, announced (Feb. 19) that the first patient has been enrolled in the Company’s Phase 1b registrational trial evaluating. The Phase 1b registrational study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by current standard-of-care therapies. Serina remains on track to initiate dosing during the current quarter, consistent with previously disclosed guidance.

Volato Group, Inc. (SOAR, $3446, +1.77%) & M2i Global, Inc. (MTWO)

  • Volato and M2i Global reaffirmed their goal of closing their business combination in the first quarter of 2026, citing steady advancement through SEC review and integration planning as they move toward a combined listing. The deal, originally announced in 2025, will effectively transition Volato from a pure‑play private aviation operator into a diversified platform spanning aviation technology and critical minerals, with M2i shareholders expected to own the majority of the combined entity. Operationally, the partnership is already visible: the two companies recently initiated their first shipment of titanium ore from Western Australia to the United States from Titanium X, underscoring how the critical‑minerals vertical could become a meaningful growth engine as domestic supply‑chain security rises in strategic importance.
  • On Feb. 4, M2i Global,Inc.along with Volato Group, Inc. announced that Titanium X has initiated its first shipment of titanium ore from Western Australia to the U.S. under its collaboration agreement.

NVIDIA (NVDA, $183.04, +1.66%)

  • Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.

McDonald’s (MCD, $331.74)

  • Options data around the February 2026 expiries highlight active positioning near the 300–305 strike range, consistent with expectations for steady but not explosive upside from here.
  • In the run-up to World Protein Day on 27th February, McDonald’s India (West & South), owned and operated by Westlife Foodworld, is celebrating Protein Week, reinforcing its leadership in nutrition-led innovation. Making protein more accessible, affordable and customizable, Indian consumers can use the McDonald’s app to explore these nutritious offerings and avail of protein burgers starting at just INR 69. Enhancing this convenience, consumers ordering via McDelivery can also enjoy free delivery on the Protein Plus meal range.

Nokia (NOK, $8.15, +.99%)

Opendoor (OPEN, $4.88)

Actelis Networks, Inc. (NASDAQ: ASNS, $.5393, +186.56%)

Actelis Networks, Inc. (NASDAQ: ASNS), a market leader in cyber-hardened, rapid-deployment networking solutions for IoT and broadband applications, today announced that it has received an order to supply its hybrid fiber-copper networking solution in support of a major California Department of Transportation (Caltrans) infrastructure modernization project in San Mateo County. The order continues a pattern of growing adoption of Actelis’ solutions by government transportation agencies across the United States.

Moderna (MRNA, $57.80, +15.99%)

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax®.

The Sources

  1. Yahoo Finance – “Stock market today: Dow, S&P 500, Nasdaq rebound on hopes of Iran deescalation as Bitcoin surges”
    https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-rebound-on-hopes-of-iran-deescalation-as-bitcoin-surges-210937794.html
  2. Yahoo Finance – “Wednesday, March 4, 2026”
    https://finance.yahoo.com/news/wednesday-march-4-2026-050300506.html
  3. Yahoo Finance – “How major US stock indexes fared Wednesday, 3/4/2026”
    https://finance.yahoo.com/news/major-us-stock-indexes-fared-212254691.html
  4. Yahoo Finance – “Stock Market News for Mar 3, 2026”
    https://finance.yahoo.com/news/stock-market-news-mar-3-142000562.html
  5. Wall Street Journal – “Stock Market Today: Dow Rises, Oil Prices Stabilize” (Live coverage, March 4, 2026)
    https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-03-04-2026
  6. Trading Economics – “United States Stock Market Index”
    https://tradingeconomics.com/united-states/stock-market
  7. Yahoo Finance – “Bitcoin High-Stakes March: $120K Forecasts Meet the $60K–$70K …”
    https://finance.yahoo.com/news/bitcoin-high-stakes-march-120k-103819836.html
  8. CoinCodex – “Bitcoin is Predicted to Reach $73,640 By Mar 03, 2026”
    https://coincodex.com/article/82290/bitcoin-prediction-february-26-2026/
  9. Robinhood – “Bitcoin price on Mar 4, 2026 at 10pm EST – Crypto Prediction Market”
    https://robinhood.com/us/en/prediction-markets/crypto/events/bitcoin-price-on-mar-4-2026-at-10pm-est-mar-03-2026/

From Coal to Code: TerraPower, Oklo and Microsoft Plug the AI Era into Next-Gen Nuclear -( $MSFT $OKLO )

America’s nuclear sector just received something rarer than bipartisan kumbaya on Capitol Hill: a first-of-its-kind commercial construction permit for an advanced reactor, signaling that the atomic age is getting a sequel with better graphics, tighter scripting—and, this time, a climate mandate. For Wall Street and Silicon Valley alike, the message is straightforward: the Nuclear Regulatory Commission is no longer a museum; it is open for new business in electrons.

Gates’ TerraPower Steps Onto Center Stage

At the center of this shift is the Natrium project in Kemmerer, Wyoming, developed by TerraPower, the nuclear innovation company founded by Bill Gates. The Natrium design is a 345 megawatt sodium-cooled fast reactor paired with a molten-salt energy storage system that can flex output to 500 megawatts—enough to power roughly 400,000 homes during peak periods. That built-in storage allows the plant to ramp like a battery while still behaving like dependable baseload, giving grid operators the kind of dispatchable, carbon-free power they usually only dream about in PowerPoint.

The Wyoming site, being built near a retiring coal plant, is the country’s flagship “coal-to-nuclear” conversion and the first utility-scale advanced nuclear project to clear a full environmental impact statement from the NRC with a recommendation that a construction permit be issued. For a technology class long trapped in pilot purgatory, breaking ground on a next-gen plant backed by Gates amounts to ringing the opening bell on an entirely new subsector of energy infrastructure.

Oklo: Microreactors for the AI Era

If TerraPower’s Natrium is the blue-chip utility play, Oklo (OKLO) is the growth stock pitching nuclear as a product for the AI age. Oklo is developing compact fast reactors—initially sub-100 megawatt units—that are designed to be factory-built, sited close to customers, and capable of running for years without refueling, eventually on recycled nuclear material. The goal is simple and audacious: turn nuclear power into something you buy in modular increments rather than as a once-in-a-generation mega-project.terrapower+1

That vision is already attracting data-center scale demand. Oklo has signed a framework agreement to deliver up to 12 gigawatts of nuclear capacity to Switch, a major data center operator whose client list includes the likes of Google and Nvidia, envisioning a fleet of microreactors rolled out through the 2040s. In parallel, Meta has lined up nuclear partnerships with Oklo, TerraPower, and others to secure roughly 6.6 gigawatts of power for its AI data centers by 2035—roughly the consumption of an entire small country. In effect, Oklo is sketching the blueprint for nuclear-powered digital campuses where the plant and the racks are designed as a single ecosystem, not separate line item.

Microsoft, Gates, and the AI Power Squeeze

All of this is unfolding against an uncomfortable arithmetic problem: AI is devouring electricity faster than grids can comfortably supply it. Forecasts suggest that data center demand could roughly double mid-decade, with AI-capable capacity growing north of 30% annually through 2030. Bill Gates has been blunt that nuclear energy is one of the few technologies capable of meeting that surge while keeping emissions in check, and TerraPower has already inked deals to serve next-generation data centers in regions where local power systems are stretched.

Microsoft, the company Gates co-founded and still influences as its most prominent alumnus, is increasingly vocal about needing new nuclear to power its cloud and AI ambitions, even going so far as to recruit small modular reactor expertise and explore nuclear-backed data center projects. That creates a neat symmetry: on one side, Gates’ TerraPower is building flexible, utility-scale reactors like Natrium; on the other, advanced players such as Oklo are designing microreactors and nuclear campuses that can plug almost directly into hyperscale facilities from Microsoft and its peers.

The result is a new strategic map where “compute” and “kilowatts” are no longer separate boardroom conversations. TerraPower’s Natrium plant in Wyoming shows that advanced reactors can clear regulatory hurdles and break ground; Oklo’s multi-gigawatt data center deals show that hyperscalers are ready to be anchor tenants; and the AI power squeeze ensures that Microsoft-level demand for firm, clean energy is not a passing fad but a structural feature of the next decade. For investors, the punchline is that nuclear is quietly reinventing itself as the backbone of the AI grid—with Bill Gates’ TerraPower providing the marquee project, Oklo supplying the modular edge, and Microsoft and its Big Tech cohort emerging as the sector’s most important new customers.

The Sources

  1. TerraPower – “NRC Approves the Natrium® Reactor Construction Permit”
    https://finance.yahoo.com/news/nrc-approves-natrium-reactor-construction-170100470.html[finance.yahoo]​
  2. Yahoo Finance – “Bill Gates-Backed TerraPower Wins Approval for 345-MW Natrium …”
    https://ca.finance.yahoo.com/news/bill-gates-backed-terrapower-wins-192554074.html[ca.finance.yahoo]​
  3. TerraPower – Natrium Advanced Reactor Overview
    https://www.terrapower.com/natrium/[terrapower]​
  4. TerraPower – “The Natrium® Project Receives First NRC-Issued Environmental Impact Statement for a Commercial Advanced Nuclear Reactor”
    https://www.terrapower.com/natrium-project-receives-first-nrc-issued-environmental-impact-statement-for-a-commercial-advanced-nuclear-reactor/[terrapower]​
  5. World Nuclear News – “US regulator accelerates review of Natrium permit”
    https://www.world-nuclear-news.org/articles/us-regulator-accelerates-review-of-natrium-permit[world-nuclear-news]​
  6. Axios – “Switch to buy 12 GW of nuclear from Oklo for data centers”
    https://www.axios.com/2024/12/18/switch-oklo-nuclear-data-centers[axios]​
  7. Utility Dive – “Oklo inks 12-GW advanced reactor supply agreement with data center developer Switch”
    https://www.utilitydive.com/news/oklo-aurora-smr-advanced-nuclear-reactor-supply-agreement-data-center-developer-switch/735933/[utilitydive]​
  8. NucNet – “Oklo Targets 12 GW Of New Nuclear Through Agreement With Data Centre Operator Switch”
    https://www.nucnet.org/news/oklo-targets-12-gw-of-new-nuclear-through-agreement-with-data-centre-operator-12-3-2024[nucnet]​
  9. Utility Dive – “Meta inks nuclear deals for up to 6.6 GW from Oklo, Vistra, TerraPower”
    https://www.utilitydive.com/news/meta-nuclear-deal-oklo-vistra-terrapower-ai-data-centers/809215/[utilitydive]​
  10. ESG News – “Meta Secures Up To 6.6 GW Nuclear Power To Fuel AI Data Center Growth”
    https://esgnews.com/meta-secures-up-to-6-6-gw-nuclear-power-to-fuel-ai-data-center-growth/[esgnews]​
  11. Power Magazine – “Meta Locks In Up to 6.6 GW of Nuclear Power Through Deals With Vistra, Oklo, and TerraPower”
    https://www.powermag.com/meta-locks-in-up-to-6-6-gw-of-nuclear-power-through-deals-with-vistra-oklo-and-terrapower/[powermag]​
  12. Yahoo Finance – “TerraPower and Meta Enter Agreement for 8 Natrium® Advanced Reactors …”
    https://finance.yahoo.com/news/terrapower-meta-enter-agreement-8-110100343.html[finance.yahoo]​
  13. Washington Is Pouring Billions Into Nuclear Energy. Does That … (Yahoo Finance)
    https://finance.yahoo.com/news/washington-pouring-billions-nuclear-energy-190200876.html[finance.yahoo]​
Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here